Facts
- Thomas Reese was convicted in May 2002 of multiple felonies including felonious assault and attempted murder and received a total prison sentence of 25 years. [lines="40-49"].
- The trial court's sentencing entry erred in stating that the consecutive sentences totaled 25 years, when they actually added up to only 23 years. [lines="56-60", "185"].
- Reese did not raise the sentencing issues in his direct appeal, focusing instead on the trial court’s supposed failure to comply with R.C. 2945.05 regarding his waiver of a jury trial. [lines="68-71"].
- In 2023, Reese attempted to correct the sentencing entry errors through a Crim.R. 36 motion, which was denied by the trial court. [lines="83-85"].
- Reese filed for a writ of habeas corpus alleging his sentence had expired as he contended he had served 23 years of his sentence by June 29, 2024. [lines="113-118"].
Issues
- Whether Reese is entitled to relief via habeas corpus, claiming that he has served his maximum sentence of 23 years. [lines="113-118"].
- Whether the warden’s argument that Reese’s habeas claim is barred by res judicata holds merit, given previous litigation on the sentencing issue. [lines="206-220"].
Holdings
- Reese has served his sentence of 23 years and is entitled to immediate release; the errors in sentencing calculations warrant the grant of the writ of habeas corpus. [lines="203-224"].
- The argument of res judicata does not apply in this case since Reese did not previously raise a claim for release based on serving his maximum sentence. [lines="206-220"].
OPINION
KIRILL VESSELOV, MIKHAIL VESSELOV, HAVEN HEALTH MANAGEMENT, LLC v. LAIRD HARRISON, MEDSCAPE LLC
No. 24-10396
United States Court of Appeals For the Eleventh Circuit
October 09, 2024
Non-Argument Calendar
Before ROSENBAUM, JILL PRYOR, and BRANCH, Circuit Judges.
D.C. Docket No. 9:23-cv-80791-DMM
PER CURIAM:
Kirill Vesselov, Mikhail Vesselov, and Haven Health Management, LLC (collectively, Plaintiffs), appeal the district court‘s order dismissing their defamation action under Florida law against Laird Harrison and Medscape LLC. Plaintiffs claimed that Harrison and Medscape defamed them in an article reporting on a judicial proceeding in which Plaintiffs were named as defendants. The district court granted Defendants’ motion to dismiss the complaint for failure to state a claim under
I.
On May 16, 2022, on its medical information and news website, www.medscape.com, Medscape published an article that journalist Harrison wrote (the “Article“). The Article summarizes the allegations and outcome of a lawsuit that Gilead Sciences, a pharmaceutical company, filed against about 58 named defendants, including Plaintiffs, based on an alleged scheme to defraud Gilead‘s low-income medication-assistance program.
HIV drugs sold on the black market. Clinics profiting from a charity program. Shady pharmacy owners purchasing mansions and jets.
Such are the accusations Gilead lodged against 58 defendants in a lawsuit alleging they profited illegally from AIDS prevention drugs that it supplies free to people who can‘t afford them.
“Together, the Kingpin Defendants defrauded Gilead‘s Charitable program of more than $68 million in less than 2 years through a fraudulent mass enrollment scheme,” wrote Gilead attorneys in a slide presentation submitted to the US District Court for the Southern District of Florida.
Gilead settled with some of the key defendants in April for an undisclosed amount. But the attorney for one group insists that her clients have been falsely accused and settled only because the court did not allow them to present their case before freezing their assets.
The Article then goes into greater detail about the medication assistance program, which provides pre-exposure prophylaxis (“PrEP“) drugs to reduce the risk of infection from HIV, and about the nature of the alleged scheme. “In the scheme alleged by Gilead,” the Article states, “the defendants sent vans to neighborhoods
The next section of the Article concerns the defendants’ reaction to the settlement, and it identifies two groups of defendants in the Gilead lawsuit. With respect to Plaintiffs, it simply states, “An attorney for two of the alleged kingpins in this scheme, Kirill and Mikhail Vesselov, declined to comment.” The Article continues, “But Robyn Lynn Sztyndor, who represents Michael Bogdan, Twiggi Batista, and a pharmacy and laboratory associated with them, denied Gilead‘s accusations.” Then, the Article includes several comments from Sztyndor, who accused Gilead of “trying to avoid giving its drugs away to people who can‘t afford the retail price” by suing clinics and pharmacies with a high volume of patients in the program, and of being “wildly talented at making up a lot of allegations that just have no factual support.” The Article further notes that Sztyndor, who she said believed in the program, denied wrongdoing by her clients and claimed that the whistleblowers had “later recanted their accusations or disappeared,” and
The Article concludes with comments from a third-party: “Whether Gilead‘s specific allegations are true, the system for providing PrEP drugs to people without insurance is vulnerable to fraud, said Barbara Kubilus, assistant director of the Behavioral Science Research Corporation, which provides staff to the Miami-Dade HIV/AIDS Partnership.” The Article includes several quotations from Kubilus, including that a pharmacy “could make a bundle” if it could get reimbursed for PrEP drugs without actually dispensing them, and that it was common for patients to sell PrEP drugs due to their scarcity in certain areas.
Before publishing the Article, Harrison, its writer, conducted an investigation into the claims by Gilead. He reviewed the pleadings, transcripts of testimony, and other documents on the record. He also contacted attorneys for both Gilead and Plaintiffs. But Harrison spoke to only an attorney that had represented Plaintiffs for a brief period, and he failed to reach out to Plaintiffs’ lead counsel in the Gilead matter, as instructed by the attorney he contacted, before finalizing the Article.
Plaintiffs Kirill Vesselov, Mikhail Vesselov, and Haven Health sued Harrison and Medscape for defamation in Florida state court, and the action was removed to federal district court under diversity jurisdiction. See
The district court dismissed Plaintiffs’ amended complaint for failure to state a claim, see
II.
We review de novo a dismissal for failure to state a claim under
Florida recognizes a qualified privilege “to make reports of judicial and quasi-judicial proceedings as long as they are accurate, fair and impartial.” Huszar v. Gross, 468 So. 2d 512, 516 (Fla. Dist. Ct. App. 1985). “The privilege extends to the publication of the contents of official documents, as long as the account is reasonably accurate and fair.” Alan v. Palm Beach Newspapers, Inc., 973 So. 2d 1177, 1180 (Fla. Dist. Ct. App. 2008).
“After the facts and circumstances of a communication are revealed, the issue of whether a privilege has been established is a question of law for the court to decide.” Tucker v. Resha, 634 So. 2d 756, 758 (Fla. Dist. Ct. App. 1994). Thus, the court may decide as a matter of law whether, based on a given set of facts, the “allegedly defamatory statements are fair, accurate and impartial.” Alan, 973 So. 2d at 1180; see Turner, 879 F.3d at 1262-63 (“[W]hether a statement of fact is susceptible to defamatory interpretation [is a] question[] of law for the court.“).
Here, Plaintiffs have not shown that the district court erred in granting Defendants’ motion to dismiss. For starters, Florida‘s fair report privilege broadly covers the Article‘s retelling of Gilead‘s allegations and claims against Plaintiffs. “It is not [defamatory] to restate prior accusations when winding up a news story,” Brake & Alignment Supply Corp. v. Post-Newsweek Stations of Fla., Inc., 472 So. 2d 517, 518 (Fla. Dist. Ct. App. 1985), even if “[s]ome of the published information may have been phrased to catch [Medscape‘s] readership‘s attention,” Alan, 973 So. 2d at 1180. The Article provided a substantially correct account of the allegations in the Gilead case, and of a notable recent occurrence in that case, namely, that Gilead had “settled with some of the key defendants in April for an undisclosed amount,” including Plaintiffs. It never stated that those allegations were true or had been admitted by Plaintiffs. So “[w]hile some of the statements in the [Article] may be viewed as painting [Plaintiffs] in a negative light, this alone does not rise to actionable defamation.” Alan, 973 So. 2d at 1180.
And the Article otherwise reasonably conveys that Gilead‘s allegations were disputed and subject to doubt. In particular, it quotes an attorney for some of Plaintiffs’ codefendants, Sztyndor, who asserted that Gilead was using “aggressive litigation” as a tactic to threaten clinics and pharmacies to “avoid giving its drugs away to people who can‘t afford the retail price.” Szytndor also stated that whistleblowers who had come forward “later recanted their accusation or disappeared,” and that Gilead was “making up a lot of allegations that just have no factual support.” In short, the Article did not depict an unfairly one-sided view of the proceeding in Gilead‘s favor.
Finally, Plaintiffs object to the Article‘s presentation of “extrajudicial expert assertions” made by Kubilus, an assistant director of an organization working with the Miami-Dade HIV/AIDS Partnership. But Kubilus did not express any opinion “[w]hether Gilead‘s specific allegations are true,” or about Plaintiffs. Instead, she simply observed that Gilead‘s medication-assistance program was “vulnerable to fraud.” Kubilus‘s comments cannot reasonably be construed as implying that Plaintiffs either did not deny or were guilty of Gilead‘s allegations.
III.
For these reasons, the district court did not err in granting Defendants’ motion to dismiss for failure to state a claim under
AFFIRMED.
